๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Locally Advanced Rectal Cancer
Clinical trial register · China

Locally Advanced Rectal Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Shanghai 5 Hubei 1 Changchun 1 Wuhan 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Shanghai5 Hubei1 Changchun1 Wuhan1
All 10 locations
Target enrolment
to

Locally Advanced Rectal Cancer trials in China

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
NCT07469306Locally Advanced Rectal Cancer
Fujian Cancer Hospital
Phase 2
130
Fuzhou, Longyan, Quanzhou
2026-08-10
Recruiting
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
NCT07150949Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
138
Shanghai
2025-08-28
Not yet open
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
NCT07074353Locally Advanced Rectal Cancer
Zhejiang Cancer Hospital
Phase 3
360
Hangzhou
2025-07-20
Recruiting
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
NCT06894797Locally Advanced Rectal Cancer
Peking University Cancer Hospital & Institute
Not applicable
68
Beijing
2025-04-01
Recruiting
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06802666Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Hubei
2024-10-16
Recruiting
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
NCT06840665Locally Advanced Rectal Cancer
Fudan University
Phase 2
46
Shanghai
2024-08-13
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
NCT06204094Locally Advanced Rectal Cancer
Jinhua Central Hospital
Phase 2
37
Jinhua
2024-02-05
Active, closed
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
NCT06056804Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Phase 2
20
Beijing
2024-01-03
Recruiting
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
NCT06234007Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Wuhan
2023-12-01
Not yet open
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT05998122Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
The First Hospital of Jilin University
Phase 2
45
Changchun
2023-09-01
Active, closed
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
NCT05585814Locally Advanced Rectal Cancer
Shanghai Changzheng Hospital
Phase 2
30
Shanghai
2023-05-01
Active, closed
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
NCT05507112Locally Advanced Rectal Cancer
Peking Union Medical College Hospital
Phase 2
100
Beijing
2022-12-20
Recruiting
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
NCT05300269Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
73
Shanghai
2022-07-05
Recruiting
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
NCT05245474Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Phase 2
186
Beijing
2022-04-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/locally-advanced-rectal-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies listing the condition Locally Advanced Rectal Cancer.

How many Locally Advanced Rectal Cancer trials are recruiting in China?

10 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Locally Advanced Rectal Cancer), 16 studies
PhaseStudiesRecruitingShare
Phase 214987.5%
Not applicable116.3%
Phase 3106.3%

Most active sponsors

Lead sponsors with the most studies (Locally Advanced Rectal Cancer)
Lead sponsorStudiesRecruiting
Fudan University33
Beijing Friendship Hospital21
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology22
Chinese PLA General Hospital11
Fujian Cancer Hospital10
Jinhua Central Hospital11
Peking Union Medical College Hospital10
Peking University Cancer Hospital & Institute11
Shanghai Changzheng Hospital10
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.